Harrow announces licensing agreement with Apotex to market 5 ophthalmic products in Canada
Products under the terms of the agreement include VERKAZIA, Cationorm PLUS, VEVYE, IHEEZO, and ZERVIATE.
Stay updated with breaking news from Markl Baum. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Products under the terms of the agreement include VERKAZIA, Cationorm PLUS, VEVYE, IHEEZO, and ZERVIATE.
Vevye® (cyclosporine ophthalmic soln) 0.1% is a preservative-free prescription medication using proprietary water-free technology.
Harrow Health, Inc. (NASDAQ:HROW – Get Free Report) saw a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 4,890,000 shares, a decline of 20.0% from the November 15th total of 6,110,000 shares. Based on an average daily trading volume, of 682,900 shares, the days-to-cover […]
Private Capital Management LLC decreased its holdings in Harrow Health, Inc. (NASDAQ:HROW – Free Report) by 1.1% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,152,346 shares of the company’s stock after selling 13,375 shares during the quarter. Harrow Health accounts for approximately […]
Prelude Capital Management LLC boosted its stake in Harrow Health, Inc. (NASDAQ:HROW – Free Report) by 6.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 46,456 shares of the company’s stock after purchasing an additional 2,753 shares during the quarter. Prelude Capital Management LLC […]